中文簡介

《胸腫瘤雜志》(JTO)是國際肺癌研究協(xié)會的官方期刊，是關(guān)于所有胸腫瘤的預(yù)防、檢測、診斷和治療相關(guān)主題的主要教育和信息出版物。JTO強(qiáng)調(diào)多學(xué)科方法，包括原始的研究綜述和觀點(diǎn)。聽眾包括流行病學(xué)家、醫(yī)學(xué)腫瘤學(xué)家、放射腫瘤學(xué)家、胸外科醫(yī)生、肺科醫(yī)生、放射科醫(yī)生、病理學(xué)家、核醫(yī)學(xué)醫(yī)生和對胸外科有特殊興趣的研究科學(xué)家。該雜志有興趣接受手稿處理流行病學(xué)，預(yù)防，篩選，早期發(fā)現(xiàn)，分期，治愈和治療胸部惡性腫瘤。有關(guān)煙草控制和戒煙的意見值得關(guān)注，特別是在與肺癌流行病學(xué)和治療結(jié)果直接相關(guān)的領(lǐng)域。該雜志也歡迎提交病理和組織學(xué)分類和新的成像和支氣管鏡方法。關(guān)于新的系統(tǒng)療法的提交，特別是在生物標(biāo)志物靶標(biāo)、基因組學(xué)、免疫學(xué)和細(xì)胞療法領(lǐng)域是有興趣的。新穎的放射治療和外科技術(shù)很有價值。鼓勵提交隨機(jī)II期和III期試驗(yàn)，以及對個體參與者數(shù)據(jù)的meta分析?；A(chǔ)科學(xué)研究必須具有直接的臨床和翻譯相關(guān)性。

投稿網(wǎng)址：http://www.editorialmanager.com/jto/default.aspx

英文簡介

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.